Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Vector signs letter of intent with LyoGenesis Plus and Wynn for IV adapter products

Vector, LyoGenesis Plus and Wynn signed a letter of intent to develop and manufacture adapter products for infusion bags and vials, focused on active ingredients on the FDA “Short List.” Production is scheduled to start in three to four months; Wynn estimates an initial market potential of more than USD 20 million annually and projects up to USD 64 million in annual revenue within five years. Vector will manage customer and sales relationships and receive about 75% of revenues; LyoGenesis Plus will act as a contract manufacturer and receive around 25% plus cost reimbursement. LyoGenesis Plus is an affiliate of Vector. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, VECTOR ACQ. CL.A DL-,0001 ha registrato ricavi pari a 205,09 Mln € e un utile netto di -43,16 Mln €

(EUR)	giu 2026	YoY
Ricavi	205,09 Mln	67,29%
Utile lordo	74,11 Mln	88,29%
Utile netto	-43,16 Mln	23,40%
EBITDA	-50,39 Mln	13,47%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	4,75 Mld €
Numero di azioni	477,65 Mln
Massimo/minimo a 52 settimane	10,20 € - 9,54 €
Dividendi	No
Beta	0,00
Rapporto P/E	-89,00
Rapporto PEG	-0,56
Rapporto P/B	2,05
Rapporto P/S	7,19

Profilo aziendale

Vector Acquisition Corp. konzentriert sich auf die Durchführung von Fusionen, Aktientausch, Übernahme von Vermögenswerten, Aktienkauf, Umstrukturierung oder ähnlichen Unternehmenszusammenschlüssen mit einem oder mehreren Unternehmen. Das Unternehmen wurde im Jahr 2020 gegründet und hat seinen Sitz in San Francisco, Kalifornien.

Nome	VECTOR ACQ. CL.A DL-,0001
CEO	Alexander R. Slusky
Sede centrale	San Francisco, ca Stati Uniti
Sito web	vectorcapital.com
Industria	Aerospaziale e difesa
Quotazione in borsa	16/11/2020